---
title: "KHPG: Pirfenidone tablets approved for listing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287213596.md"
description: "KHPG recently announced that it has obtained the \"Drug Registration Certificate\" for Pirfenidone Tablets issued by the National Medical Products Administration, approving its registration. Pirfenidone Tablets are classified as a Class II psychotropic drug, primarily used for the treatment of neurological disorders associated with neuronal hyperexcitability"
datetime: "2026-05-21T11:47:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287213596.md)
  - [en](https://longbridge.com/en/news/287213596.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287213596.md)
---

# KHPG: Pirfenidone tablets approved for listing

According to the Zhitong Finance APP, KHPG (002773.SZ) announced that it recently received the "Drug Registration Certificate" (Certificate No.: 2026S01622, 2026S01623) for Pirfenidone Tablets issued by the National Medical Products Administration, approving its registration.

The active ingredient of Pirfenidone Tablets is Pirfenidone, which is classified as a Class II psychotropic drug according to the national "Regulations on the Administration of Narcotic Drugs and Psychotropic Substances." Pirfenidone is a non-competitive antagonist of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor on postsynaptic neurons. Glutamate is the main excitatory neurotransmitter in the central nervous system and is involved in various neurological diseases caused by neuronal hyperexcitability

### Related Stocks

- [002773.CN](https://longbridge.com/en/quote/002773.CN.md)

## Related News & Research

- [14:03 ETMIND EXPANDING SPECIALIZED NEUROLOGICAL SERVICES TO WESTLAND THIS SUMMER](https://longbridge.com/en/news/290726359.md)
- [09:18 ETHKeyBio Debuts HKEY-ExE™ 1.0 to Address Preclinical Bottlenecks in EoE and EgE Drug Development](https://longbridge.com/en/news/290701010.md)
- [Aton unit Pims Technology advances talks to deploy PIMS Q8 oncology platform at European cancer centers](https://longbridge.com/en/news/290884272.md)
- [Coiled Therapeutics: AO-252 delivers promising clinical results and commercial potential as the only clinical-stage TACC3 inhibitor](https://longbridge.com/en/news/290784764.md)
- [07:02 ETNewforma invests in future AECO leaders with new scholarship program](https://longbridge.com/en/news/290955262.md)